1. All Products
  2. DORASOVE - Sofosbuvir / Velpatasvir
  3. SOFOSBUVIR (SOF) 400mg / VELPATASVIR (VEL) 100mg, tab.
Public Pricelist

SOFOSBUVIR (SOF) 400mg / VELPATASVIR (VEL) 100mg, tab.

https://unicat.msf.org/cat/product/70332
STD DORASOVE41T

Valid Article

Former Code(s): DORASOVE4T-
6.4.4.2.1 - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AP55
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

SOFOSBUVIR (SOF) / VELPATASVIR (VEL)

Therapeutic Action

Fixed-dose combination of a nucleotide analogue NS5B polymerase inhibitor (sofosbuvir) and an HCV NS5A inhibitor (velpatasvir)

Indications

Chronic Hepatitis C (CHC) infection

Some restricted information has been hidden. Sign in to see this information

Instructions for use

The dosage 200 mg / 50 mg is intended for paediatric use.

Precautions for Use

Contraindicated in pregnancy and breast-feeding.

Storage

Below 25°C